Enlivex Therapeutics (Nasdaq: ENLV) unveiled a strategic roadmap following compelling Phase IIa data for Allocetra™ in knee osteoarthritis, showing a 72% reduction in pain and 109% improvement in function in patients aged 60+, a demographic that represents over half of the 32M+ U.S. KOA market. With statistically significant results surpassing FDA efficacy thresholds and strong endorsements from leading experts, Enlivex is advancing toward Phase IIb in 2026, positioning Allocetra™ as a potential first-in-class, disease-modifying therapy for a rapidly growing patient population.

Gorilla Technology (Nasdaq: GRRR) has secured a multi-million-dollar government contract in Asia for its AI-powered IPDR analytics platform—its second national enforcement win in the past month—solidifying its role as the prime AI vendor for digital intelligence across the APAC region. The platform will deliver GPU-as-a-Service capabilities for a leading cybercrime bureau, enabling real-time forensic reconstruction and national-scale AI model training—firmly positioning Gorilla at the forefront of AI-driven smart policing and cyber-resilience infrastructure.

BullFrog AI (Nasdaq: BFRG) successfully leveraged its bfPREP™ platform to convert over 10,000 pages of Eleison Pharmaceuticals’ legacy clinical trial data into structured, AI-ready formats then deployed its bfLEAP® analytics engine to uncover actionable insights for improved patient targeting. The collaboration highlights the power of BullFrog’s scalable, enterprise-grade tools to enhance trial efficiency and design, with a joint oncology conference submission in the works and follow-on contract discussions already underway.

FibroBiologics (Nasdaq: FBLG) announced major advancements in its Bone Marrow Organoid platform, showing tumor reduction in preclinical melanoma models and enabling ex vivo gene editing for precision therapy. With cryopreservation capabilities and potential applications spanning cancer, immune regeneration, and even in-vivo CAR-T/CAR-NK cell generation, the platform is advancing toward IND-enabling studies—positioning FibroBiologics at the forefront of scalable, next-gen immune and oncology therapeutics.